Key Findings
- In metastatic urothelial cancer, low CXCL9:SPP1 ratios derived from Caris molecular profiling were associated with reduced immune infiltration and worse outcomes following pembrolizumab or enfortumab vedotin plus pembrolizumab therapy.
- These studies’ findings show how integrated genomic, transcriptomic, and immune microenvironment profiling can identify biologically distinct genitourinary cancer subgroups and potential biomarkers of therapeutic response and resistance.